I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the 2021 SITC Annual Meeting
Developed in collaboration with ABL, TJ-CD4B/ABL111 and TJ-L14B/ABL503 are part of
TJ-CD4B/ABL111 engages the Claudin18.2 (CLDB18.2) tumor antigen mainly on gastric and pancreatic cancers to produce localized T-cell activation at the cancer site. It has demonstrated a strong affinity to CLDN18.2-positive cancer cells even at low levels of CLDN18.2 and has potential application in a wide range of cancers. TJ-CD4B/ABL111 is currently undergoing phase 1 trials in the
TJ-L14B/ABL503 is a novel bi-specific antibody targeting both PD-L1 and 4-1BB. It engages the PD-L1 molecule on cancer cells and exerts a strong anti-tumor activity through localized activation of T-cells and it is designed to overcome the limited efficacy of anti-PD-L1 therapies and anti-4-1BB-related toxicity. TJ-L14B/ABL503 is currently undergoing a phase 1 clinical trial in the
Details of the poster discussion session are as follows:
Abstract Number: 702
Title: TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumor-dependent immune response without dose-limiting toxicity in preclinical studies
Poster Session: Poster hall, 12-14th
Presenter: Dr.
Abstract Number: 892
Title: ABL503 (TJ-L14B), PD-L1x4-1BB bispecific antibody induces superior anti-tumor activity by PD-L1-dependent 4-1BB activation with the increase of 4-1BB+CD8+ T cells in tumor microenvironment
Poster Session: Poster Hall, 12-14th
Presenter: Dr. Gihoon You, ABL Bio
###
About TJ-CD4B/ABL111
TJ-CD4B, also known as ABL111, is a Claudin 18.2 and 4-1BB bispecific antibody capable of binding to tumor cells expressing Claudin 18.2, i.e., gastric cancer and pancreatic cancer cells, and stimulating intra-tumoral T cells by the 4-1BB arm designed to be activated only upon tumor engagement while silent elsewhere. TJ-CD4B effectively maintains a strong tumor binding property and anti-tumor activity attributable to a synergistic effect of both Claudin 18.2 antibody and 4-1BB antibody while it avoids or minimizes liver toxicity and systemic immunotoxicity commonly seen with 4-1BB antibodies as a drug class. TJ-CD4B is being developed under collaboration between I-Mab and ABL.
About TJ-L14B/ABL503
Being developed jointly with ABL, TJ-L14B/ABL503 is a differentiated PD-L1-based bispecific antibody with the PD-L1 arm as the tumor-dependent T-cell activator and the 4-1BB arm as the conditional T cell activator upon tumor engagement. Using ABL's "Grabody-T" bispecific antibody platform technology, TJ-L14B/ABL503 stimulates 4-1BB activation only in the presence of PD-L1 expressing tumor cells to minimize the risk of off-tumor toxicity. Preclinical studies have demonstrated that the bispecific antibody shows better anti-tumor activity than equimolar doses of single agents alone or in combination.
About
About ABL Bio
ABL Bio, Inc. (Kosdaq: 298380) is a South Korean biotechnology company developing antibody therapeutics for immuno-oncology and neurodegenerative diseases. With internal R&D and global partnerships, ABL has developed multiple BsAb platforms, such as "Grabody-T," "Grabody-I" and "Grabody-B" and built an innovative pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, ABL has developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated superior efficacy and safety. In the neurodegenerative disorder space, ABL has developed Grabody-B platform, which is designed to maximize blood-brain barrier (BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. For more information, please visit www.ablbio.com
I-Mab Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding data from the TJ-CD4B and TJ-L14B preclinical studies, the potential implications of clinical data for patients, and
ABL Forward Looking Statements
Statements in this press release contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform act of 1995. Words such as "will," "could," "hope," "expect," "plan" and similar expressions that are based on ABL's current expectations and assumptions are subject to risks and uncertainties that are difficult to predict. The risks and uncertainties include but are not limited to, potential delays in clinical trial recruitment and participation; ABL and
I-Mab Contacts
Jielun Zhu +86 21 6057 8000
|
+86 21 6057 5709
|
Investor Inquiries
E-mail: emilie@thepiacentegroup.com Office line: +86 21 6039 8363 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-and-abl-bio-to-present-preclinical-data-of-tj-cd4babl111-and-tj-l14babl503-at-the-2021-sitc-annual-meeting-301392656.html
SOURCE